Miami, FLNCT06798012Now EnrollingIRB Ready

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trial in Miami, FL

Access cutting-edge chronic inflammatory demyelinating polyradiculoneuropathy treatment through this phase 2 clinical trial at a research site in Miami. Study-provided care at no cost to qualified participants.

Sponsored by Takeda

Quick Self-Assessment

See if you qualify for this Miami location

Preparing your pre-screening questions…

Expert Care in Miami

Access chronic inflammatory demyelinating polyradiculoneuropathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic inflammatory demyelinating polyradiculoneuropathy treatment provided free

Apply for This Miami Location

Check if you qualify for this chronic inflammatory demyelinating polyradiculoneuropathy clinical trial in Miami, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Miami

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Miami site if eligible
  4. 4Begin participation

About This Chronic Inflammatory Demyelinating Polyradiculoneuropathy Study in Miami

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globu

Sponsor: Takeda

Who Can Participate

Inclusion Criteria

The participant is at least 18 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
The participant has a body weight of less than or equal to (\<=) 150 kilogram (kg).
The participant has a documented diagnosis of typical CIDP, as confirmed by a neurologist specializing/experienced in neuromuscular diseases and consistent with the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021 criteria.
The participant has responded to IgG treatment in the past (documented partial or complete resolution of neurological symptoms and deficits).
The participant has had disease activation within 24 months before screening, as documented in medical records and in the opinion of the investigator, defined as one of the following:
Clinically meaningful deterioration of symptoms on interruption or dose reduction of IgG treatment.
Clinically meaningful deterioration of symptoms requiring IgG treatment dose increase with subsequent clinical improvement.
Clinically meaningful deterioration of symptoms at the end of IgG treatment dose interval with improvement after next dose administration.
The participant is on a stable dose of immunoglobulin treatment intravenously (IGIV) treatment, (within the dose range of 0.4 to 2.4 grams per kilogram \[g/kg\] every 2 to 6 weeks \[inclusive\]). A stable dose is defined as no change greater than 10 percentage (%) in frequency or dose of IGIV therapy within the 3 months before and throughout screening.
The participant has an INCAT score between 0 and 7 (inclusive) at screening. Key

Exclusion Criteria

The participant has a documented diagnosis of a CIDP variant per EAN/PNS 2021 criteria.
The participant has any neuropathy of other causes, including the following:
Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy, Charcot-Marie-Tooth disease, and hereditary sensory and autonomic neuropathies.
Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and nondiabetic lumbosacral radiculoplexus neuropathy, lymphoma, amyloidosis.
Multifocal motor neuropathy.
Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy.
Diabetic peripheral neuropathy.
The participant has any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or that may interfere with assessment of CIDP or outcome measures, including (but not limited to) multiple sclerosis, arthritis, stroke, and Parkinson's disease.
The participant is required to take or has taken either of the following for treatment of CIDP:
Immunomodulatory/immunosuppressive agents (except IGIV) that include, but are not limited to, complement inhibitors, efgartigimod, and chemotherapeutic drugs, within 3 months or 5 half-lives, whichever is longer, of screening.
B-cell affecting biologics (e.g. rituximab) within 6 months of screening. Note: Participants on a long-term, stable dosing regimen of certain immunomodulatory agents (eg, hydroxychloroquine) for any disease other than CIDP may be eligible, provided the dose regimen has been stable for 3 months before screening and is expected to remain stable throughout the study.
The participant has undergone plasma exchange within 3 months of screening.
The participant has a history of malignancy with less than 2 years of complete remission before screening, or active malignancy requiring chemotherapy and/or radiotherapy. Note: Participants with adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment are eligible.
The participant has experienced deep vein thrombosis or arterial thromboembolic events (example, cerebrovascular accident, pulmonary embolism) within 12 months of screening.
The participant has any medical condition, laboratory finding, or physical examination finding that precludes participation or with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the study or place the participant at undue medical risk.
The participant has participated in another clinical study involving an IP or investigational device within 30 days before screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Miami?

Yes, this clinical trial (NCT06798012) has an active research site in Miami, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treatment Options in Miami, FL

If you're searching for chronic inflammatory demyelinating polyradiculoneuropathy treatment options in Miami, FL, this clinical trial (NCT06798012) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Miami research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic inflammatory demyelinating polyradiculoneuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic inflammatory demyelinating polyradiculoneuropathy clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Miami, FL

See all multiple myeloma clinical trials recruiting in Miami — not just this study.

Browse Multiple Myeloma Trials in Miami →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsAlzheimers Disease TrialsNeuropathy TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Miami?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Miami, FL